Once-Daily Orforglipron Tablet Outperformed Placebo for Weight Loss

CATEGORY: DIET & WEIGHT

Adults with obesity who took the highest dose of a once-daily pill lost an average of 11.2% of their body weight in 72 weeks. On placebo the figure was 2.1%. The pill is orforglipron, and the trial behind those numbers enrolled 3,127 adults and ran in the New England Journal of Medicine.¹ Sold as Foundayo, it was approved by American regulators in April 2026 as the first weight-loss drug of its kind that comes as a tablet with no food or water restrictions.

Why This One Can Be Swallowed With Breakfast

Orforglipron belongs to the GLP-1 receptor agonist family. These drugs copy a gut hormone that tells your brain you are full and slows how quickly your stomach empties. The most effective members so far, semaglutide and tirzepatide, arrive as weekly injections. One earlier tablet version did exist, but it had to be taken on an empty stomach with a long wait before eating. Orforglipron is a small molecule rather than a copy of the hormone itself, and that chemistry is what lets it be swallowed at any hour of the day.¹

Three Doses, and a Dummy Tablet That Looked the Same

The trial was called ATTAIN-1. It enrolled adults who had obesity but not diabetes, at sites in several countries. A randomization list decided who swallowed 6, 12 or 36 milligrams a day and who swallowed the identical-looking placebo, and neither the participants nor their doctors were told which. Everyone got the same advice on eating and physical activity. Body weight was measured in clinic across 72 weeks, and the headline number counted every person randomized, whether or not they stayed on the tablets. That is a more realistic picture of ordinary use than counting only the people who finished. Percent change in body weight at week 72 was the prespecified main endpoint, and every dose beat placebo on it.¹

54.6% Crossed the One-Tenth Mark

Average loss ran 7.5% at the lowest dose and 8.4% at the middle one. At 36 milligrams it reached 11.2%, against 2.1% on placebo. Among people on the top dose, 54.6% lost at least a tenth of their body weight, 36.0% lost at least 15% and 18.4% lost at least a fifth. The matching placebo figures were 12.9%, 5.9% and 2.8%. Waist size, systolic blood pressure, triglycerides and non-HDL cholesterol all moved further in the drug’s favor.¹

Nausea, Eli Lilly, and the Questions Left Open

Digestive complaints dominated the side-effect list: nausea, constipation and similar troubles, mostly mild to moderate. Between 5.3% and 10.3% of people on orforglipron quit over side effects, against 2.7% on placebo. Eli Lilly, which makes the drug, paid for the trial. Seventy-two weeks is a short window for a lifelong condition, so what happens over many years, or after the tablets stop, went untested here. People with diabetes were excluded, and the pill was never put head-to-head against the injectable drugs.¹

Oral GLP-1 drugs have been pooled once already. A 2026 analysis pooling nine randomized trials, with 5,766 adults who had overweight or obesity and no diabetes, found every drug tested except one low-dose option beat a dummy pill on weight loss, with orforglipron and the highest dose of oral semaglutide showing the largest effects. The reviewers graded the certainty of that evidence as low to moderate.²

Key Takeaways

• At 36 milligrams a day, orforglipron produced 11.2% average weight loss over 72 weeks, against 2.1% on placebo, among 3,127 adults with obesity.
• About one in three people on the top dose lost 15% or more of their body weight; on placebo it was closer to one in seventeen.
• Digestive side effects were common and mostly mild to moderate, and roughly one in ten on the top dose stopped because of them.
• The trial ran 72 weeks, excluded people with diabetes, and never compared the tablet against the injectable GLP-1 drugs.

References

1. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796–1806. link
2. Kamrul-Hasan ABM, Ashraf H, Nagendra L, et al. Role of oral glucagon-like peptide-1 receptor agonists in weight management for individuals with overweight or obesity without diabetes: a network meta-analysis of randomized controlled trials. Obesity Science & Practice. 2026;12(4):e70181. link.